Lack of Clinical Relevance of ANA and ASMA Positivity in Patients with Liver Transplantation without a History of Autoimmune Diseases

Table 1

Study population characteristics (114 patients).

Variables
Median age at the time of transplantation (range)	53 years (1–67)
of males (%)	76 (66.7)
Cause of transplantation (%)
(i) HBV	39 (34.2)
(ii) HCV	57 (50)
(iii) Other	18 (15.8)
HCC at the time of transplantation (%)	40 (35)
Early liver rejection (%)	27 (23.7)
Time from transplantation (0-time of the transplant) (%)
(i) >3 months–1 year	11 (9.6)
(ii) >1 year–5 years	27 (23.7)
(iii) >5 years–10 years	26 (22.8)
(iv) >10 years	50 (43.9)
Age group at 0
(i) ≤50 years	15 (13.2)
(ii) >50–60 years	34 (29.8)
(iii) >60 years	65 (57)
Therapy at the time of the study (constant during the study) (%)
(i) Cyclosporine	32 (28.1)
(ii) Tacrolimus	55 (48.2)
(iii) Mycophenolate	12 (10.5)
(iv) Everolimus	15 (13.2)

: alcoholic cirrhosis, 2: polycystic liver disease, 1: congenital fibrosis, 1: Wilson’s disease, and 4: nonalcoholic liver disease.